Estradiol .05 mg/d (Estradiol PATCH) .05 mg/d

Estradiol acts as an agonist at estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and estrogenic effects in target tissues. This mechanism helps alleviate symptoms of estrogen deficiency and supports the maintenance of bone density.

The dosage of Estradiol .05 mg/d is determined by a healthcare provider based on the individual's condition and response to treatment. It is typically applied as a transdermal patch once or twice weekly, depending on the specific formulation and prescription.

Estradiol .05 mg/d is contraindicated during pregnancy as it may cause fetal harm. It should also be used with caution during breastfeeding, as estrogen can pass into breast milk. Always consult a healthcare provider for personalized advice.

To order Estradiol .05 mg/d from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then provide pricing, availability, shipping details, and the necessary import paperwork.

Estradiol .05 mg/d is a transdermal patch that delivers estrogen directly through the skin, which can reduce the risk of certain side effects associated with oral estrogen therapies, such as liver toxicity. It is particularly effective for managing menopausal symptoms and preventing osteoporosis in postmenopausal women.

Estradiol .05 mg/d should be stored at 20 to 25°C (68 to 77°F), with excursions permitted to 15 to 30°C (59 to 86°F). Do not store unpouched. Apply the patch immediately upon removal from the protective pouch. Used patches should be folded with the sticky side together, placed in a sturdy child-proof container, and discarded in the trash.

Estradiol .05 mg/d is administered as a transdermal patch. The patch should be placed on a clean, dry area of the lower abdomen or buttocks. It should not be applied to the breasts. The patch is typically changed once or twice weekly, depending on the specific formulation and prescription.

The most serious risks associated with Estradiol .05 mg/d include an increased risk of endometrial cancer (in women with a uterus), breast cancer, venous thromboembolism (blood clots), stroke, heart attack, gallbladder disease, and dementia in postmenopausal women over 65. Regular monitoring and follow-up with a healthcare provider are essential.

Estradiol .05 mg/d should not be used by individuals with undiagnosed abnormal vaginal bleeding, known or suspected estrogen-dependent neoplasms, active deep vein thrombosis, or a history of blood clots. It is also contraindicated during pregnancy and should be used with caution in women with certain medical conditions, such as liver disease or a history of breast cancer.